

*This copy is for your personal, non-commercial use only.*

If you wish to distribute this article to others, you can order high-quality copies for your colleagues, clients, or customers by [clicking here](#).

Permission to republish or repurpose articles or portions of articles can be obtained by following the guidelines [here](#).

**The following resources related to this article are available online at [www.sciencemag.org](http://www.sciencemag.org) (this information is current as of October 11, 2010):**

**Updated information and services**, including high-resolution figures, can be found in the online version of this article at:

<http://www.sciencemag.org/cgi/content/full/329/5996/1201>

**Supporting Online Material** can be found at:

<http://www.sciencemag.org/cgi/content/full/science.1191241/DC1>

A list of selected additional articles on the Science Web sites **related to this article** can be found at:

<http://www.sciencemag.org/cgi/content/full/329/5996/1201#related-content>

This article **cites 19 articles**, 7 of which can be accessed for free:

<http://www.sciencemag.org/cgi/content/full/329/5996/1201#otherarticles>

This article has been **cited by** 1 articles hosted by HighWire Press; see:

<http://www.sciencemag.org/cgi/content/full/329/5996/1201#otherarticles>

This article appears in the following **subject collections**:

Molecular Biology

[http://www.sciencemag.org/cgi/collection/molec\\_biol](http://www.sciencemag.org/cgi/collection/molec_biol)

particles driving the expression of zyxin-GFP, zyxin- $\Delta 2/3$ LIM-GFP, or GFP, respectively (fig. S11). Delivery of zyxin to the vaginal epithelium did not result in increased exfoliation of the uninfected mucosa (fig. S11). However, zyxin, but not zyxin- $\Delta 2/3$ LIM, overexpression blocked the colonization of CEATg mice by Opa<sub>CEA</sub>-expressing gonococci (Fig. 4D). The overexpression of zyxin, but not of zyxin- $\Delta 2/3$ LIM, allowed exfoliation of CEA-positive cells infected with Ngo Opa<sub>CEA</sub> and reestablished the responsiveness of the vaginal mucosa (Fig. 4E and fig. S11). Thus, CEA-initiated up-regulation of CD105 on superficial epithelial cells and the resulting delocalization of zyxin from integrin-rich focal adhesion sites are the critical molecular events that allow CEACAM-binding microorganisms to counteract the exfoliation response.

Although symptomatic gonococcal infection in humans might be a multistep process orchestrated by additional virulence factors (13, 23), our results establish a specific role of Opa<sub>CEA</sub> proteins in promoting mucosal colonization. In vivo challenge experiments with male volunteers have revealed that after infection of the urethra with non-opaque gonococci, bacteria re-isolated from these volunteers almost invariably converted to an Opa protein-expressing phenotype (24, 25). In addition to the urogenital tract, members of the CEACAM family are present on all mucosal surfaces including the nasopharynx (26). These mucosal habitats are colonized by several Gram-

negative bacterial species, which make use of unrelated protein adhesins to engage human CEACAMs (27–31). The blockage of epithelial exfoliation afforded by CEACAM binding might have driven this convergent evolution that allows specialized bacteria to transform the mucosa into a dependable platform for colonization.

#### References and Notes

1. J. P. Pearson, I. A. Brownlee, in *Colonization of Mucosal Surfaces*, J. P. Nataro, P. S. Cohen, H. L. T. Mobley, J. N. Weiser, Eds. (ASM Press, Washington, DC, 2005), pp. 3–16.
2. M. A. Mulvey *et al.*, *Science* **282**, 1494 (1998).
3. M. A. Mulvey, J. D. Schilling, J. J. Martinez, S. J. Hultgren, *Proc. Natl. Acad. Sci. U.S.A.* **97**, 8829 (2000).
4. I. U. Mysorekar, M. A. Mulvey, S. J. Hultgren, J. I. Gordon, *J. Biol. Chem.* **277**, 7412 (2002).
5. P. Muenzner, M. Rohde, S. Kneitz, C. R. Hauck, *J. Cell Biol.* **170**, 825 (2005).
6. M. Kim *et al.*, *Nature* **459**, 578 (2009).
7. WHO, *Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections—Overview and Estimates* (World Health Organization, Geneva, 2001).
8. M. A. Melly, C. R. Gregg, Z. A. McGee, *J. Infect. Dis.* **143**, 423 (1981).
9. Z. A. McGee, A. P. Johnson, D. Taylor-Robinson, *J. Infect. Dis.* **173**, 413 (1981).
10. K. F. Tjia, J. P. van Putten, E. Pels, H. C. Zanen, *Graefes Arch. Clin. Exp. Ophthalmol.* **226**, 341 (1988).
11. I. M. Mosleh, H. J. Boxberger, M. J. Sessler, T. F. Meyer, *Infect. Immun.* **65**, 3391 (1997).
12. See supporting material on Science Online.
13. M. Virji, *Nat. Rev. Microbiol.* **7**, 274 (2009).
14. M. Voges, V. Bachmann, R. Kammerer, U. Gophna, C. R. Hauck, *BMC Microbiol.* **10**, 117 (2010).
15. C. R. Hauck, T. F. Meyer, *Curr. Opin. Microbiol.* **6**, 43 (2003).

16. A. M. Eades-Perner *et al.*, *Cancer Res.* **54**, 4169 (1994).
17. J. P. van Putten, S. M. Paul, *EMBO J.* **14**, 2144 (1995).
18. T. Chen, R. J. Belland, J. Wilson, J. Swanson, *J. Exp. Med.* **182**, 511 (1995).
19. B. A. Conley *et al.*, *J. Biol. Chem.* **279**, 27440 (2004).
20. G. Zambruno *et al.*, *J. Cell Biol.* **129**, 853 (1995).
21. M. Guerrero-Esteo *et al.*, *Eur. J. Cell Biol.* **78**, 614 (1999).
22. L. M. Hoffman *et al.*, *J. Cell Biol.* **172**, 771 (2006).
23. A. J. Merz, M. So, *Annu. Rev. Cell Dev. Biol.* **16**, 423 (2000).
24. J. Swanson, O. Barrera, J. Sola, J. Boslego, *J. Exp. Med.* **168**, 2121 (1988).
25. A. E. Jerse *et al.*, *J. Exp. Med.* **179**, 911 (1994).
26. S. Hammarström, *Semin. Cancer Biol.* **9**, 67 (1999).
27. M. Virji, K. Makepeace, D. J. P. Ferguson, S. M. Watt, *Mol. Microbiol.* **22**, 941 (1996).
28. M. Virji *et al.*, *Mol. Microbiol.* **36**, 784 (2000).
29. D. J. Hill, M. Virji, *Mol. Microbiol.* **48**, 117 (2003).
30. C. N. Berger, O. Billker, T. F. Meyer, A. L. Servin, I. Kansau, *Mol. Microbiol.* **52**, 963 (2004).
31. M. Toleman, E. Aho, M. Virji, *Cell. Microbiol.* **3**, 33 (2001).
32. We thank M. C. Beckerle for zyxin-deficient fibroblasts and antibodies; M. Chudakov for the mKate cDNA; J. W. Greiner for sending the CEATg mice; T. F. Meyer for bacterial strains; D. W. Piston for cDNA of mCerulean; A. J. Schaeffer for hVEC cells; D. Vestweber for providing antibody; C. Hentschel, J. Scharrer, and R. Mak'anyengo for assistance with SEM; and B. Planitz for expert animal care. Supported by Deutsche Forschungsgemeinschaft grant Ha2856/6-1 (C.R.H.).

#### Supporting Online Material

www.sciencemag.org/cgi/content/full/329/5996/1197/DC1

Materials and Methods

Figs. S1 to S10

References

14 April 2010; accepted 30 June 2010

10.1126/science.1190892

## Signaling Kinase AMPK Activates Stress-Promoted Transcription via Histone H2B Phosphorylation

David Bungard,<sup>1</sup> Benjamin J. Fuerth,<sup>2,3</sup> Ping-Yao Zeng,<sup>1,4</sup> Brandon Faubert,<sup>2,3</sup> Nancy L. Maas,<sup>1</sup> Benoit Viollet,<sup>5,6</sup> David Carling,<sup>7</sup> Craig B. Thompson,<sup>8</sup> Russell G. Jones,<sup>2,3,8\*</sup> Shelley L. Berger<sup>1,9,10\*</sup>

The mammalian adenosine monophosphate-activated protein kinase (AMPK) is a serine-threonine kinase protein complex that is a central regulator of cellular energy homeostasis. However, the mechanisms by which AMPK mediates cellular responses to metabolic stress remain unclear. We found that AMPK activates transcription through direct association with chromatin and phosphorylation of histone H2B at serine 36. AMPK recruitment and H2B Ser<sup>36</sup> phosphorylation colocalized within genes activated by AMPK-dependent pathways, both in promoters and in transcribed regions. Ectopic expression of H2B in which Ser<sup>36</sup> was substituted by alanine reduced transcription and RNA polymerase II association to AMPK-dependent genes, and lowered cell survival in response to stress. Our results place AMPK-dependent H2B Ser<sup>36</sup> phosphorylation in a direct transcriptional and chromatin regulatory pathway leading to cellular adaptation to stress.

Signaling pathways often involve cascades of protein phosphorylation that terminate in regulation of nuclear transcription. However, the central kinases in these pathways are generally not thought to directly modulate transcription. One such signaling kinase, adenosine monophosphate-activated protein kinase (AMPK) (1), is activated by high substrate adenosine monophosphate levels under conditions of energetic stress, such as nutrient deprivation or hypoxia. AMPK activation initiates a program of

metabolic adaptation to preserve cellular energy (adenosine triphosphate conservation) and maintain cellular viability (2).


We investigated possible direct transcriptional mechanisms in the AMPK pathway. First, we examined whether AMPK broadly responds to cellular stress. Mouse embryonic fibroblasts (MEFs) were stressed by ultraviolet (UV) irradiation,  $\gamma$  irradiation, the topoisomerase inhibitor camptothecin, the DNA intercalating agent adriamycin, the alkylating agent *N*-methyl-*N'*-nitro-*N*-

nitrosoguanidine, or hydrogen peroxide. AMPK was activated [Thr<sup>172</sup> phosphorylation in the AMPK activation loop and phosphorylation of substrate ACC $\alpha$  (acetyl coenzyme A-carboxylase- $\alpha$ )] by all agents (Fig. 1A). Liver kinase B1 (LKB1) is one of three mammalian upstream AMPK kinases and activates AMPK upon bioenergetic stress (3). LKB1 also activated AMPK in response to either genotoxic (UV irradiation) or metabolic stress [the glycolytic inhibitor 2-deoxyglucose (2-DG)] (fig. S1).


<sup>1</sup>Department of Cellular and Developmental Biology, University of Pennsylvania Medical School, Philadelphia, PA 19104, USA. <sup>2</sup>Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec H3G 1Y6, Canada. <sup>3</sup>Department of Physiology, McGill University, Montreal, Quebec H3G 1Y6, Canada. <sup>4</sup>Institutes of Biomedical Sciences Epigenetics Program, Mingdao Building, Room 511, Fudan University, Mail Box 281, 138 Yixue Yuan Road, Shanghai 200032, P.R. China. <sup>5</sup>Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), 75014 Paris, France. <sup>6</sup>INSERM U1016, 75014 Paris, France. <sup>7</sup>Cellular Stress Group, MRC Clinical Sciences Centre, Imperial College, Hammersmith Hospital, London W12 0NN, UK. <sup>8</sup>Abramson Cancer Center and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA. <sup>9</sup>Department of Genetics, University of Pennsylvania Medical School, Philadelphia, PA 19104, USA. <sup>10</sup>Department of Biology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA 19104, USA.

\*To whom correspondence should be addressed. E-mail: russell.jones@mcgill.ca (R.G.J.); bergers@mail.med.upenn.edu (S.L.B.)

**Fig. 1.** AMPK is required for stress-dependent transcription and localizes to stress-responsive genes. **(A)** Western blot of AMPK activation (AMPK $\alpha$  pThr<sup>172</sup>) and ACC $\alpha$  phosphorylation (ACC $\alpha$  pSer<sup>79</sup>) in MEFs in response to UV light,  $\gamma$  irradiation (IR), camptothecin (CPT), adriamycin (Adr), *N*-methyl-*N*-nitro-*N*-nitrosoguanidine (MNNG), or hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>). Exposure times were 6 hours for UV, IR, CPT, and Adr and 30 min for MNNG and H<sub>2</sub>O<sub>2</sub>. NT, no treatment; Glc, glucose. **(B)** Viability of wild-type (WT) and *ampk $\alpha$* <sup>-/-</sup> MEFs in response to indicated stresses. Left panel: glucose (Glc) withdrawal; right panel, UV irradiation (UVC). **(C)** Expression (qPCR) of *p21*, *cpt1c*, and *gapdh* mRNA in wild-type, AMPK $\alpha$ -deficient, or p53 RNAi-expressing MEFs after glucose withdrawal, relative to untreated cells. **(D)** ChIP of WT or dominant negative (MUT) myc-AMPK after glucose withdrawal in *lkb1*<sup>-/-</sup> MEFs cotransfected with either WT or catalytically inactive (MUT) FLAG-LKB1, both able to be immunoprecipitated [see (A), fig. S7, and (5)]. Data represent means  $\pm$  SEM for *n* = 3. **(E to G)** Endogenous AMPK $\alpha$ 2 ChIP in untreated MEFs (-), 2-DG (15 min), or UV (6 hours) (E); WT or *ampk $\alpha$* <sup>-/-</sup> MEFs (F); and WT or *p53*<sup>-/-</sup> MEFs (G). Data represent means  $\pm$  SEM for *n* = 3. #*P* < 0.06, \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.03.



**Fig. 2.** H2B is an AMPK target. **(A to D)** In vitro phosphorylation by myc-AMPK immunoprecipitated from *ampk $\alpha$* <sup>-/-</sup> MEFs of recombinant human histones by beads alone, WT myc-AMPK, or catalytic mutant (D157A) myc-AMPK (right: myc Western blot) (A); recombinant human histones using myc-AMPK from glucose-treated cells (+glucose) or untreated cells (-glucose) (B); H2B peptides (C); and H2B 21-42 and SAMS peptide (D). **(E)** Western blots of wild-type or *ampk $\alpha$* <sup>-/-</sup> MEFs treated with 2-DG (25 mM for 10 min) or untreated. **(F)** Western blots of MEFs treated for 1 hour with AICAR (AIC, 2 mM) or phenformin (Ph, 3 mM) or untreated.



We next used wild-type or AMPK $\alpha$ 1- and AMPK $\alpha$ 2-deficient MEFs (*ampka*<sup>-/-</sup>) to examine whether AMPK influences cellular survival during stress (4). The *ampka*<sup>-/-</sup> MEFs displayed decreased survival in the presence of metabolic stressors (Fig. 1B and fig. S2), UV irradiation (Fig. 1B), or hydrogen peroxide (fig. S2), indicating that AMPK promotes cell survival in response to various metabolic and genotoxic stresses.

Our previous work implicated AMPK and LKB1 in tumor suppressor p53-dependent metabolic and genotoxic stress responses (2, 5). We examined the involvement of AMPK in transcriptional regulation of p53-responsive genes. *ampka*<sup>-/-</sup> MEFs showed decreased induction of *p21*, a well-characterized p53 target gene, in response to both glucose withdrawal and UV irradiation (Fig. 1C and fig. S3). The reduction in glucose-regulated gene expression was similar in magnitude to knockdown of p53 (Fig. 1C). Other p53-dependent genes, including *reprimo*, *cyclinG*, and *cpt1c*, showed reduced expression in *ampka*<sup>-/-</sup> cells deprived of glucose, whereas expression of

a control gene, *gapdh*, was unaffected (Fig. 1C and fig. S4). A similar defect in stress-dependent transcription was observed in human cancer cells (HCT116 colon carcinoma) (fig. S5). The transcriptional defect observed in UV-treated cells occurred downstream of the DNA-damage checkpoint, as phosphorylation of Chk1, Rad17, and p53 in both *lkb1*<sup>-/-</sup> and *ampka*<sup>-/-</sup> cell lines was similar to that of wild-type controls (fig. S6). Thus, in cell culture, the LKB1-AMPK pathway responds to a wide variety of metabolic and genotoxic stresses and is required for maximal stress-induced transcription of multiple p53-dependent genes that promote survival.


These and previous results (6) implicate AMPK in gene activation, although the underlying mechanisms have remained elusive. We used chromatin immunoprecipitation (ChIP) and quantitative polymerase chain reaction (qPCR) to investigate whether AMPK plays a direct role at p53-regulated genes in MEFs. We found that LKB1 coimmunoprecipitated with AMPK in response to UV irradiation, and this interaction was dependent on

AMPK kinase activity (fig. S7). ChIP showed ectopic myc-AMPK associated with the *cpt1c* and *p21* gene promoters in response to glucose withdrawal and UV treatment (Fig. 1D and fig. S8). Ectopic kinase-deficient myc-AMPK $\alpha$  or FLAG-tagged LKB1 abrogated the binding of AMPK to chromatin (Fig. 1D and fig. S8). FLAG-LKB1 similarly associated with the *p21* promoter (fig. S9). Binding of AMPK or LKB1 to promoters in unstressed cells was low (Fig. 1D and figs. S8 and S9). AMPK was also detected at the *p21* promoter in human HCT116 cells after UV treatment (fig. S10). This AMPK activation appears to be specific for survival in response to stress, because AMPK was not detected at the PUMA promoter, a p53-dependent, pro-apoptotic gene (fig. S11). The immunoprecipitation and ChIP results suggest a functional, kinase-dependent interaction and promoter association of LKB1 and AMPK.

ChIP of endogenous AMPK, using an AMPK $\alpha$ 2 antibody that immunoprecipitated the protein (fig. S12), showed increased AMPK $\alpha$ 2 binding at p53 sites upstream of *cpt1c* in cells treated with 2-DG and UV light (Fig. 1E; at the *p21* promoter, fig. S13). The binding was reduced in both *ampka*<sup>-/-</sup> cells (Fig. 1F) and *p53*<sup>-/-</sup> cells (Fig. 1G). Thus, in response to cellular stress, LKB1 and AMPK physically localize to chromatin in an interdependent and p53-dependent fashion to regulate gene transcription.

Posttranslational modifications of core histones, including phosphorylation, function to regulate transcription (7, 8). To examine histones as substrates of AMPK, we epitope-tagged the predominantly nuclear isoform AMPK $\alpha$ 2 (9) and immunoprecipitated wild-type AMPK $\alpha$ 2 or a catalytic mutant (Asp<sup>157</sup> → Ala) from transfected *ampka*<sup>-/-</sup> MEFs after low glucose treatment to activate AMPK. The wild-type AMPK $\alpha$ 2 complex specifically phosphorylated histone H2B above the nonspecific background activity of all four histones observed in the catalytic mutant and mock immunoprecipitations (Fig. 2A). AMPK $\alpha$ 2 from untreated cells exhibited low activity on H2B relative to AMPK $\alpha$ 2 from stressed cells (Fig. 2B and fig. S15). H2A was also phosphorylated in these assays; however, phospho-H2A was detected in the mock immunoprecipitation and did not respond to stress, which suggested that the activity is nonspecific. These data indicate that activated AMPK $\alpha$ 2 specifically phosphorylates H2B.

Analysis of histone H2B revealed a potential AMPK target motif (10, 11) at Ser<sup>36</sup> in the N terminus, similar to the AMPK substrates endothelial nitric oxide synthase (eNOS) and phosphofructokinase 2 (PFK2) (H2B, Arg-Ser-Arg-Lys-Glu-Ser; eNOS, Arg-Ile-Arg-Thr-Gln-Ser; PFK2, Arg-Met-Arg-Arg-Asn-Ser), with conserved Arg residues at P-5 and P-3 relative to the phosphoacceptor Ser<sup>36</sup> (fig. S14) (12). We therefore compared peptides corresponding to residues 1 to 20 or 21 to 42 of H2B; only the H2B 21-42 peptide was phosphorylated by immunoprecipitated AMPK $\alpha$ 2. Moreover, an H2B 21-42



**Fig. 3.** AMPK and H2B p536 are localized to chromatin in response to stress. **(A)** Western blots showing myc-AMPK immunoprecipitation from WT H2B- or H2B S36A-expressing cells after AICAR treatment (1 mM, 24 hours). WCL, whole-cell lysate. **(B)** ChIP in WT or *ampka*<sup>-/-</sup> MEFs. Data represent means  $\pm$  SEM for *n* = 3. **(C and D)** ChIP along *cpt1c* gene (C) and *p21* gene (D) with glucose (white bars) or without glucose (black bars). Data represent means  $\pm$  SEM for *n* = 3. \**P* < 0.01, \*\**P* < 0.05.

peptide harboring a Ser<sup>36</sup> → Ala (S36A) substitution was not phosphorylated, whereas S32A and S38A peptides were phosphorylated (Fig. 2C). In addition, myc-AMPK $\alpha$ 2 phosphorylated the H2B 21-42 peptide more efficiently than did SAMS (His-Met-Arg-Ser-Ala-Met-Ser-Gly-Leu-His-Leu-Val-Lys-Arg-Arg), a canonical AMPK target sequence (Fig. 2D) (13). Thus, H2B Ser<sup>36</sup> is a robust in vitro AMPK substrate.


We next examined whether AMPK is involved in the regulation of H2B Ser<sup>36</sup> phosphorylation in vivo. We generated an antibody against an H2B pS36 peptide and extensively characterized the affinity-purified antibody in vitro and in vivo (fig. S16). H2B pS36 occurs in cells treated with 2-DG, which induced metabolic stress shown by increased phosphorylation of AMPK $\alpha$  and ACC $\alpha$  (Fig. 2E), whereas other histone marks, including H3, K9me3 H3, and pS10 H3, did not significantly change (fig. S17). In *ampka*<sup>-/-</sup> MEFs, H2B pS36 did not increase after 2-DG treatment (Fig. 2E). We detected similar induction of H2B pS36 in cells with two well-characterized AMPK activators, aminoimidazole carboxamide ribonucleotide (AICAR) and phenformin (Fig. 2F). In

addition, H2B pS36 was not detected in *lkb1*<sup>-/-</sup> MEFs but increased after reintroduction of LKB1, and 2-DG stimulated H2B pS36 only when LKB1 was present (fig. S18). These results suggest that H2B Ser<sup>36</sup> phosphorylation is downstream of the LKB1-AMPK signaling pathway in vivo in response to a broad range of metabolic stresses, and that AMPK is likely the direct kinase in this pathway. This global increase of H2B pS36 may not be limited to p53 target genes (Fig. 1G), because H2B pS36 levels were not reduced in *p53*<sup>-/-</sup> cells (fig. S19).

We found that transfected myc-AMPK and FLAG-H2B associate in 293T cells in response to the AMPK agonist AICAR (Fig. 3A). This interaction was ablated by an H2B S36A mutation (Fig. 3A), suggesting that Ser<sup>36</sup> is critical for the interaction of AMPK and H2B. We next performed ChIP experiments in wild type and *ampka*<sup>-/-</sup> MEFs to determine whether H2B pS36 is associated with AMPK-dependent genes, specifically at the p53 binding site in the *cpt1c* promoter. The H2B pS36 ChIP signal increased in response to both 2-DG and UV treatment, and the ChIP signal was reduced to background levels in AMPK $\alpha$ -deficient cells (Fig. 3B).

To compare the locations of endogenous AMPK and H2B pS36, we performed ChIP at *cpt1c* under normal and glucose-free conditions, using primers along the promoter, transcribed region, and upstream or downstream nontranscribed regions (Fig. 3C, primer sets 1 to 7). Upon stress, an increase in H2B pS36 occurred at the p53 binding site (p53bs, primer set 2), a larger increase at the transcription start site (TSS, primer set 4), and only background levels upstream (primer set 1) and between (primer set 3) these sites, and downstream of the gene (primer set 7) (Fig. 3C). Notably, H2B pS36 associated throughout the transcribed region of *cpt1c* (primer sets 5 and 6) (Fig. 3C). We then used the AMPK $\alpha$ 2 antibody and discovered a positive correlation between locations of endogenous AMPK and H2B pS36, again with localization throughout the transcribed region (Fig. 3C). The *p21* gene showed a similar positive correlation between H2B pS36 and endogenous AMPK localization at the p53 binding sites and along the transcribed region, but not around the gene and only in response to low glucose (Fig. 3D). As a control, we tested the *gapdh* gene, which showed no difference in ChIP signal between the stressed and unstressed cells (fig. S20). Similar results were observed at the *cpt1c* gene in response to UV treatment (fig. S21). Ectopic myc-AMPK also localized along the *p21* transcribed gene in response to low glucose and required AMPK catalytic activity (fig. S22). This correspondence in the location of AMPK and H2B pS36 suggests that the role of AMPK in transcriptional regulation is linked to the phosphorylation of H2B along transcribed regions of target genes.

We generated clonal MEF cell lines with stable ectopic expression of FLAG-H2B or mutant FLAG-H2B S36A, and, as shown above, only FLAG-H2B was detected by the H2B pS36 antibody (fig. S16). The level of FLAG-tagged wild-type or mutant histone H2B was lower than that of endogenous H2B as measured by Western blot (fig. S23); however, both ectopic wild-type and H2B S36A similarly incorporated into chromatin, as determined by ChIP and qPCR at the promoter and transcribed region of the *cpt1c* gene (fig. S24) and by coimmunoprecipitation of endogenous H3 and H2B with FLAG-H2B as shown by Western blot (fig. S25). We isolated several equivalently expressing FLAG-H2B- and FLAG-H2B S36A-expressing clonal lines (fig. S26). The cell lines treated with 2-DG showed comparable levels of AMPK and induction of AMPK Thr<sup>172</sup> and pACC $\alpha$  Ser<sup>79</sup> phosphorylation (fig. S27), suggesting that signaling to AMPK is unaffected by the S36A mutation. In response to glucose withdrawal, elevated transcription of the AMPK target genes *p21*, *cpt1c*, *reprimo*, and *cyclinG* was detected in wild-type FLAG-H2B-expressing cells; however, FLAG-H2B S36A-expressing cells showed significantly reduced induction of these genes (Fig. 4A). Expression of the control genes *gapdh* and *hadh* was unaffected by expression of the S36A mutant (fig. S28). Thus, although expression of FLAG-H2B is low relative to endogenous H2B (figs. S23



**Fig. 4.** H2B Ser<sup>36</sup> is essential for transcription and survival in response to metabolic stress. Data for MEF cell lines expressing wild-type H2B or H2B S36A are shown. (A) Relative expression (qPCR) of indicated genes after glucose withdrawal in individual MEF clones (H2B, clones 5 and 6; H2B S36A, clones 4 and 6). (B) Viability of H2B (open squares) or H2B S36A (solid squares) MEFs in no glucose, 2-DG (10 mM), or phenformin (3 mM). (C) ChIP of RNA Pol II across the *cpt1c* gene. Data represent means  $\pm$  SEM for  $n = 3$ . \* $P < 0.05$ , \*\* $P < 0.01$ , # $P < 0.03$ , ## $P < 0.08$ .

and S25), we observed a significant and specific transcriptional defect in the cells ectopically expressing S36A mutant H2B.

We next tested the viability of these cells in response to various metabolic stresses including glucose withdrawal, 2-DG, and phenformin. The level of cell death induced by these stresses was significantly greater in the presence of ectopic H2B S36A, relative to cells expressing ectopic wild-type H2B (Fig. 4B).

Finally, we examined whether RNA polymerase II (Pol II) occupancy at genes is altered by ectopic expression of H2B S36A. ChIP analysis showed that Pol II was present through the *cpt1c* gene, and Pol II increased in glucose withdrawal (Fig. 4C). In FLAG-H2B S36A cells, the Pol II ChIP signal was reduced along the transcribed region of the *cpt1c* gene specifically under conditions of glucose withdrawal (Fig. 4C). These data point to AMPK-mediated phosphorylation of H2B at Ser<sup>36</sup> as a critical transcriptional regulatory step in the cellular adaptation response to stress, to optimize cell survival.

Our results show that AMPK directly associates with chromatin to regulate transcriptional programs required to survive a wide variety of metabolic and environmental stresses. Mammalian AMPK is a histone kinase that preferentially phosphorylates histone H2B at Ser<sup>36</sup>. Phosphorylation of this site in vivo is acutely dependent on the LKB1-AMPK energy-sensing pathway, and through their direct action at genes.

AMPK and H2B pS36 appear to regulate transcription by direct interaction between the kinase and the H2B substrate. AMPK appears to be recruited to specific promoters by transcription factors such as p53. AMPK may similarly influence other stress-induced transcriptional activators, including Foxo3a, peroxisome proliferator-activated

receptor  $\gamma$  coactivator 1 $\alpha$  (PGC-1 $\alpha$ ), and transducer of regulated CREB activity 2 (TORC2) (2, 14–16). AMPK colocalizes with and phosphorylates H2B at p53 binding sites and along the transcribed *cpt1c* and *p21* genes. This pattern may be due to activator recruitment of the enzyme, followed by enzyme transit across transcribed regions, as seen for the SAGA-Gcn5-Ubp8 complex and in the acetylation of H3 with deubiquitination of H2B (17, 18). Moreover, histone methylases associate with RNA Pol II to modify H3 across transcribed regions (19). Our findings represent evidence for histone phosphorylation across transcribed regions, which suggests that AMPK, via H2B Ser<sup>36</sup> phosphorylation, may play a role in transcriptional elongation.

Ectopic expression of the H2B S36A mutant, even in the presence of higher levels of endogenous wild-type H2B, significantly reduces transcription of AMPK target genes and stress survival. Hence, the modification may function processively to facilitate transcription elongation. Indeed, H2B Ser<sup>36</sup> phosphorylation promotes RNA Pol II association to transcribed regions. Ectopic expression of mutant histone genes may be of broad utility to unravel functions of other histone modifications in mammalian cells.

As part of the central energy-sensing pathway in eukaryotes, AMPK functions to maintain cellular energy homeostasis in the face of metabolic perturbations. Our data suggest that modification of H2B by AMPK may be a general stress-response pathway to tune specific transcriptional responses, regulate cellular metabolism, and promote cell survival.

#### References and Notes

1. D. G. Hardie, *Nat. Rev. Mol. Cell Biol.* **8**, 774 (2007).
2. R. G. Jones *et al.*, *Mol. Cell* **18**, 283 (2005).
3. D. G. Hardie, *Curr. Opin. Cell Biol.* **17**, 167 (2005).

4. K. R. Laderoute *et al.*, *Mol. Cell Biol.* **26**, 5336 (2006).
5. P. Y. Zeng, S. L. Berger, *Cancer Res.* **66**, 10701 (2006).
6. S. L. McGee, M. Hargreaves, *Front. Biosci.* **13**, 3022 (2008).
7. S. L. Berger, *Nature* **447**, 407 (2007).
8. M. S. Ivaldi, C. S. Karam, V. G. Corces, *Genes Dev.* **21**, 2818 (2007).
9. C. J. Salt *et al.*, *Biochem. J.* **334**, 177 (1998).
10. D. M. Winn *et al.*, *Mol. Cell* **30**, 214 (2008).
11. J. Weekes, K. L. Ball, F. B. Caudwell, D. G. Hardie, *FEBS Lett.* **334**, 335 (1993).
12. M. C. Towler, D. G. Hardie, *Circ. Res.* **100**, 328 (2007).
13. D. G. Hardie, I. P. Salt, S. P. Davies, *Methods Mol. Biol.* **99**, 63 (2000).
14. R. J. Shaw *et al.*, *Science* **310**, 1642 (2005).
15. E. L. Greer *et al.*, *J. Biol. Chem.* **282**, 30107 (2007).
16. S. Jäger, C. Handschin, J. St-Pierre, B. M. Spiegelman, *Proc. Natl. Acad. Sci. U.S.A.* **104**, 12017 (2007).
17. C. K. Govind, F. Zhang, H. Qiu, K. Hofmeyer, A. G. Hinnebusch, *Mol. Cell* **25**, 31 (2007).
18. A. Wyce *et al.*, *Mol. Cell* **27**, 275 (2007).
19. A. Shilatifard, *Annu. Rev. Biochem.* **75**, 243 (2006).
20. Supported by NIH grants CA078831 (S.L.B.) and CA105463 (C.B.T.), NIH Training Program in Basic Cancer Research grant CA09171 (D.B.), Canadian Institutes of Health Research grant MOP-93799 (R.G.J.), the McGill Integrated Cancer Research Training Program (B.F.), and the Leukemia and Lymphoma Society, NIH, National Cancer Institute, and American Association for Cancer Research (AACR)/Stand Up to Cancer (C.B.T.). C.B.T. reports the filing of patent applications exploiting the use of AMPK activators in cancer therapy. He is also a member of the board of directors of Merck, the scientific advisory board of Agios Pharmaceuticals, and the medical advisory board of the Howard Hughes Medical Institute.

#### Supporting Online Material

www.sciencemag.org/cgi/content/full/science.1191241/DC1  
Materials and Methods  
Figs. S1 to S28  
References

21 April 2010; accepted 23 June 2010

Published online 15 July 2010;

10.1126/science.1191241

Include this information when citing this paper.

## The Junctional Adhesion Molecule JAML Is a Costimulatory Receptor for Epithelial $\gamma\delta$ T Cell Activation

Deborah A. Witherden,<sup>1</sup> Petra Verdino,<sup>2</sup> Stephanie E. Rieder,<sup>1\*</sup> Olivia Garijo,<sup>1</sup> Robyn E. Mills,<sup>1†</sup> Luc Teyton,<sup>1</sup> Wolfgang H. Fischer,<sup>4</sup> Ian A. Wilson,<sup>2,3</sup> Wendy L. Havran<sup>1‡</sup>

$\gamma\delta$  T cells present in epithelial tissues provide a crucial first line of defense against environmental insults, including infection, trauma, and malignancy, yet the molecular events surrounding their activation remain poorly defined. Here we identify an epithelial  $\gamma\delta$  T cell–specific costimulatory molecule, junctional adhesion molecule–like protein (JAML). Binding of JAML to its ligand Coxsackie and adenovirus receptor (CAR) provides costimulation leading to cellular proliferation and cytokine and growth factor production. Inhibition of JAML costimulation leads to diminished  $\gamma\delta$  T cell activation and delayed wound closure akin to that seen in the absence of  $\gamma\delta$  T cells. Our results identify JAML as a crucial component of epithelial  $\gamma\delta$  T cell biology and have broader implications for CAR and JAML in tissue homeostasis and repair.

**K**ey players in cellular immunity,  $\alpha\beta$  and  $\gamma\delta$  T cells, fulfill distinct, yet equally important, functions.  $\alpha\beta$  T cells are primarily involved in foreign antigen recognition, whereas

$\gamma\delta$  T cells function in tissue homeostasis and recognition of damaged self (1–3). Epithelial  $\gamma\delta$  T cells reside at the interface between organism and environment. They provide a rapid response to

environmental insults and are crucial to the maintenance of epithelial integrity (2, 4, 5).  $\gamma\delta$  T cells in the skin, also known as dendritic epidermal T cells (DETCs), are a prototypic epithelial  $\gamma\delta$  T cell population. DETCs have cellular projections that are in constant contact with multiple neighboring keratinocytes and Langerhans cells (6) and are activated after interaction with damaged or malignant keratinocytes (2, 4). DETC activation likely relies on the interplay of numerous cell surface molecules, as for  $\alpha\beta$  T cell activation, but the underlying mechanisms of DETC activation are unknown. Furthermore, many of

<sup>1</sup>Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA. <sup>2</sup>Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. <sup>3</sup>The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. <sup>4</sup>Peptide Biology, The Salk Institute, La Jolla, CA 92037, USA.

\*Present address: Abbott Bioresearch Center, Worcester, MA 01605, USA

†Present address: University of California, San Francisco, San Francisco, CA 94143, USA

‡To whom correspondence should be addressed. E-mail: havran@scripps.edu.